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Abstract
To determine the accuracy with which Medicare claims data measure disease-free survival in
elderly Medicare beneficiaries with cancer, we performed a criterion validation study. We merged
gold-standard clinical trial data of 45 elderly patients with node-positive breast cancer who were
treated on the Cancer and Leukemia Group B (CAL-GB) adjuvant breast trial 9344 with Centers
for Medicare and Medicaid Services (CMS) data files and compared the results of a CMS-based
algorithm with the CALGB disease-free survival information to determine sensitivity and
specificity. For 5-year disease-free survival, the sensitivity of the CMS-based algorithm was 100%
(95% confidence interval [CI] = 81% to 100%), the specificity was 97% (95% CI = 83% to
100%), and the area under the receiver operator curve was 97% (95% CI = 90% to 100%). For 2-
year disease-free survival, the test characteristics were less favorable: sensitivity was 83% (95%
CI = 36% to 100%), specificity was 95% (95% CI = 83% to 100%), and area under the receiver
operator curve was 84% (95% CI = 66% to 100%).
The elderly are numerically under-represented (1–3) and possibly physiologically
misrepresented (4) in clinical trials of cancer chemotherapy such that trial participants are
potentially younger and healthier than the average elderly cancer patient. The general
population of elderly Americans therefore may not experience the same benefits and
toxicities of chemotherapy as trial participants. Nevertheless, clinicians need information
about the expected benefits and toxicities of chemotherapy in the elderly. A solution to this
problem is to supplement clinical trial results with observational results. Prior research has
shown that Centers for Medicare and Medicaid Services (CMS) data can be used to
accurately measure chemotherapy use (5,6), but the extent to which it can be used to
measure outcomes that are traditionally reported in clinical trials, including conventional
survival and toxicity endpoints, is unknown.
Disease-free survival is one of the most common survival metrics in adjuvant chemotherapy
trials and is defined as the time from enrollment to the first of two events: cancer relapse or
death from any cause. Disease-free survival incorporates the morbidity associated with
recurrent disease that overall survival does not and is thus most relevant to those cancers
with long periods between recurrence and death (e.g., local or regionally advanced cancers
of the breast, prostate, colon, and rectum). Indeed, the Food and Drug Administration has
accepted disease-free survival as a regulatory endpoint that demonstrates clinical benefit for
adjuvant therapy.
We are unaware of previous attempts to measure disease-free survival through Medicare
claims. This absence is not due to an inability to measure survival—the accuracy of CMS
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tvital status information is well established (7). Rather, it is the result of ambiguity regarding
the ability of claims to capture cancer recurrence. As a preliminary study to determine the
accuracy with which Medicare claims data capture disease-free survival in elderly breast
cancer patients, we developed an algorithm for measuring both disease recurrence and death
using Medicare data files and compared the results with an external gold-standard measure
of disease-free survival, Cancer and Leukemia Group B (CALGB) clinical trial data.
The model cohort included all patients aged ≥ 65 years (n = 52) who consented, enrolled,
and were treated on CALGB trial 9344, “Doxorubicin dose escalation, with or without
Taxol, as part of the CA adjuvant regimen for node positive breast cancer” between January
1, 1995, and December 31, 1997. These 52 patients represented only 5.5% (52 of 944) of the
full enrollment during this period. Despite what seems like a small percentage of elderly
enrollees, the trial was chosen because the absolute value of enrolled elderly was among the
largest of all phase 3 trials during that period.
We then carefully linked the patients’ CALGB clinical trial data (e.g., disease-free survival
information) to their CMS Medicare claims files (i.e., denominator, Carrier, Outpatient, and
MedPAR files) from enrollment through December 31, 2000 (8). We were able to match 51
(98%) of the 52 patients to Medicare files, a rate consistent with previous studies (9). Six
patients were excluded because they were enrolled in health maintenance organizations and
their claims were not processed through CMS (n = 3) or because they were not enrolled in
Medicare part B (n = 3). Thus, the final analytic sample contained 45 patients.
This study was approved by the University of Chicago and Massachusetts General Hospital
institutional review boards and conducted in compliance with their regulations. Data quality
was ensured by careful review of data by CALGB Statistical Center staff and by the study
chairperson. Statistical analyses were approved and confirmed by CALGB statisticians. All
analyses were two-sided and performed using STATA version 8 SE; P<.05 was considered
statistically significant.
We developed and ultimately refined a clinically intuitive algorithm to measure disease-free
survival that required screening patients’ Medicare claims from the calendar date of their
enrollment on CALGB 9344 forward through their last Medicare claim up to December 31,
2000 (the last day of available claims files), for evidence of cancer relapse or death. In
clinical medicine, cancers are described according to primary anatomic sites (i.e., where the
tumor originates) and secondary anatomic sites (i.e., location of tumor spread). The primary
anatomic site is well documented in Surveillance, Epidemiology, and End Results (SEER)
(10) and may be reasonably well documented in CMS files (11). However, whether (or
when) the tumor has spread to anatomically distinct sites is not reported or measured by
SEER, and it is not known whether such events are captured reliably in CMS claims.
Because CMS claims use International Classification of Diseases 9th Revision–Clinical
Modification (ICD-9-CM) diagnostic codes that do have distinct values for primary and
secondary cancer sites, it is at least theoretically possible that CMS claims distinguish
primary anatomic malignancy sites from secondary sites of primary cancer spread.
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tIn CMS files, we identified cancer relapse by evaluating MedPAR, Carrier, and Outpatient
files for ICD-9 diagnostic codes indicating secondary sites of cancer (Table 1) and then
dated the relapse by “claim through date.” From the universe of ICD-9-CM secondary sites
of cancer codes, we omitted the code 198.2 indicating “secondary malignant neoplasm of the
breast” to avoid erroneous overcoding of patients’ primary breast cancer as “relapse” and
ultimately omitted the code 198.89 “ secondary malignant neoplasm of unspecified site”
because of its high false-positive rate. Date of death was obtained from CMS denominator
files. The first of the two possible events (i.e., relapse or death) was chosen to represent
disease-free survival according to CMS claims. Individuals without either event were
censored at the date of their last CMS claim with a maximum date of December 31, 2000.
We compared CMS disease-free survival information with the gold standard of CALGB
disease-free survival information (censored at December 31, 2000) to calculate sensitivity,
specificity, and area under the receiver operator curve of the disease-free survival indicator
during the entire follow-up period and at traditional trial–censoring points (i.e., 2 years and 5
years). We defined sensitivity as the proportion of the patients known (according to CALGB
data) to have either died or relapsed who were correctly identified through CMS claims as
such. We defined specificity as the proportion of the patients known (according to CALGB
data) to be both alive and without disease relapse who were correctly identified through
CMS claims as such. The global performance of the measures was summarized by the area
under the receiver operator curve (graph of sensitivity versus 1 – specificity); the greater the
area under the receiver operator curve (maximum 1.00), the better the discriminatory
accuracy of the measure.
The sample was exclusively female, the mean age was 69.6 years (standard deviation ± 4.2
years), and 82% were white, 11% black, and 7% Hispanic. During the entire follow-up
period (i.e., a maximum of 2162 days in the CALGB data source and 2142 days in the CMS
data source), 15 (33%) of the 45 patients had relapsed or had died according to CMS claims.
By comparison, the gold-standard source of survival information noted, as a first event,
relapse or death in 14 (31%) of 45 (P = .84) (Supplementary Figure, available at http://
jncicancerspectrum.oxfordjournals.org/jnci/content/vol98/issue18). The 5-year disease-free
survival sensitivity (100%, 95% confidence interval [CI] = 83% to 100%), specificity (97%,
95% CI = 87% to 100%), and area under the receiver operator curve (97%, 95% CI = 90%
to 100%) were favorable, each being more favorable than 2-year disease-free survival
(sensitivity = 83%, 95% CI = 36% to 100%; specificity = 95%, 95% CI = 83% to 100%; and
area under the receiver operator curve = 84%, 95% CI = 66% to 100%) (Table 2).
We compared results of the CMS algorithm to the gold-standard data source with respect to
the three components of disease-free survival (i.e., relapse, death, and censoring) at 5 years.
According to the gold-standard data source, 86% (12 of 14) of the disease-free survival
failures were the result of relapsed disease and 14% (2 of 14) were the result of death (Table
3). The ICD-9-CM codes for “secondary malignant neoplasm” applied to CMS data
correctly categorized 11 of these 12 relapsed patients in CALGB data (sensitivity = 92%,
95% CI = 66% to 100%) and correctly categorized 31 of the 33 nonrelapsed patients
(specificity = 94%, 95% CI = 82% to 99%).
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tWe measured the patient-level difference in the gold-standard and CMS algorithm time
variables. The median difference in CALGB compared with CMS time was 40 days, and the
inter-quartile range was 12–86 days. The mean difference was 99 days (95% CI = 4.5 to 193
days).
This preliminary validation study of Medicare claims shows that for elderly Medicare
beneficiaries with histories of lymph node–positive breast cancer who were treated on a
randomized phase 3 CALGB adjuvant chemotherapy trial, contemporaneous Medicare
claims files reflect subsequent 5-year disease-free survival with a high degree of accuracy.
The algorithm appears to also distinguish relapse from death within the domain of disease-
free survival, which suggests that the secondary anatomic site codes may capture cancer
recurrence. Taken with results of prior work documenting the ability of CMS claims to
accurately measure certain anticancer therapies (6,12,13), these results suggest that CMS
data capture some key elements of the clinical trial paradigm, and thus existing CMS-based
data sources (e.g., SEER-Medicare) may be leveraged to yield clinical information regarding
the effectiveness of adjuvant cancer treatments in the general population of elderly with
solid tumors. Future research will focus on confirming these findings in a larger and more
diverse patient sample.
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Lamont et al. Page 7
Table 1
Algorithm for measuring disease-free survival in Centers for Medicare and Medicaid Services (CMS) claims
files
Code type Value Description
ICD-9 Dx* 197.0 Secondary malignant neoplasm of the lung
197.1 Secondary malignant neoplasm of the mediastinum
197.2 Secondary malignant neoplasm of the pleura
197.3 Secondary malignant neoplasm of other respiratory organs
197.4 Secondary malignant neoplasm of the small intestine, including duodenum
197.5 Secondary malignant neoplasm of the large intestine and rectum
197.6 Secondary malignant neoplasm of the retroperitoneum and peritoneum
197.7 Secondary malignant neoplasm of the liver
197.8 Secondary malignant neoplasm of the other digestive organs and spleen
198.0 Secondary malignant neoplasm of the kidney
198.1 Secondary malignant neoplasm of other urinary organs
198.2 Secondary malignant neoplasm of the skin
198.3 Secondary malignant neoplasm of the brain and spinal cord
198.4 Secondary malignant neoplasm of the other parts of the nervous system
198.5 Secondary malignant neoplasm of the bone and bone marrow
198.6 Secondary malignant neoplasm of the ovary
198.7 Secondary malignant neoplasm of the adrenal gland
198.8 Secondary malignant neoplasm of other sites
198.82 Secondary malignant neoplasm of the genital organs
Death indicator† Date of death Field contains date of death of Medicare beneficiary
*
ICD-9 = International Classification of Diseases 9th Revision codes applied to CMS ambulatory and hospital files (i.e., Carrier, Outpatient,
MedPAR).
†
CMS denominator file.
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Lamont et al. Page 8
Table 2
Test characteristics of the Centers for Medicare and Medicaid Services (CMS) disease-free survival algorithm*
Censoring Period Sensitivity (95% CI) Specificity (95% CI) Area under ROC (95% CI)
2 y 83% (36% to 100%) 95% (83% to 100%) 84% (66% to 100%)
5 y 100% (81% to 100%) 97% (83% to 100%) 97% (90% to 100%)
*
The test characteristics were estimated by comparing CMS files with gold-standard clinical trial data pertaining to 45 elderly women with lymph
node–positive breast cancer treated on the adjuvant chemotherapy trial CALGB 9344. CI = confidence interval; ROC = receiver operator curve.
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Lamont et al. Page 9
Table 3
Five-year disease-free survival (disease-free survival) censoring proportions for Cancer and Leukemia Group
B (CALGB) versus Centers for Medicare and Medicaid Services (CMS) data
Censoring category CMS data CALGB gold-standard data
disease-free survival = 1
  Relapsed 13 12
  Dead 2 2
disease-free survival = 0
  Censored 30 31
Total 45 45
J Natl Cancer Inst. Author manuscript; available in PMC 2014 September 09.